Month: August 2019

HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development

Articles

FDA urges Pharma giants to increase their inclusion of men in new Breast Cancer trials The recent FDA recommendations have urged the Pharma...

Read More

What lies in the future for NASH upcoming drugs?

Business Consultant, DelveInsight's Drug Report, Pharma Consultant, Snippets

NAFLD is one of the leading causes of liver damage in the younger population. The increasing NAFLD prevalence runs parallel with the...

Read More

What to expect in the coming years for Hairy Cell Leukemia therapy landscape?

Articles, Business Consultant, DelveInsight's Drug Report, Pharma Consultant

Every 3 minutes, one person in the United States (U.S.) is diagnosed with blood cancer, as estimated by The Leukemia & Lymphoma Society...

Read More

Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario?

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Oncology based Reports, Pharma Consultant

The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The...

Read More

FDA approves first-ever Non-Controlled treatment for Excessive Daytime Sleepiness with Narcolepsy

Business Consultant, DelveInsight's Drug Report, Pharma Consultant, Snippets

The U.S. Food and Drug Administration has approved WAKIX (pitolisant) to treat excessive daytime sleepiness (EDS) in adult patients with...

Read More

Juvenescence nets USD 100M; Sarepta DMD drug faces rejection; Researchers enhance neuron recovery

Business Consultant, DelveInsight's Drug Report, Notizia, Pharma Consultant, The Business Cocktail

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has...

Read More
Close